角膜基质修复与再生
角膜是透明无血管的免疫豁免组织,提供约三分之二的眼屈光力。本综述讨论角膜修复、恢复与再生的近期进展,概述小分子药物、基因治疗、纳米医学、干细胞、营养因子、外泌体、基质等效物、生物工程基质支架、组织黏合剂和3D生物打印等不断发展的方法与治疗模式,这些方法在恢复角膜透明度和功能方面显示出很大前景。
要点
- 角膜提供约三分之二的眼屈光力,损伤、感染和遗传因素可致视力损害。
- 目前主要用激光/非激光手术、免疫抑制剂和/或角膜移植恢复视力。
- 小分子药物、基因治疗、纳米医学、干细胞、外泌体、生物工程支架和3D生物打印等是新兴治疗方向。
核心结论
- 基于机制理解开发精准引导、组织靶向的非手术疗法促进角膜修复与再生,对减轻全球盲症影响至关重要。
研究设计与样本
- 本文为综述,讨论角膜修复、恢复与再生领域的近期进展。
主要发现
- 过去十年研究表明,多种治疗递送方法调控病理信号通路和因子,在多种临床前动物模型中有效治疗角膜瘢痕/混浊、炎症和血管生成,并已准备进入人体转化。
- 综述概述了小分子药物、基因治疗、纳米医学、干细胞、营养因子、外泌体、基质等效物、生物工程基质支架、组织黏合剂和3D生物打印等不断发展的方法与治疗模式。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The cornea is a specialized, transparent, avascular, immune-privileged, and heavily innervated tissue that affords 2/3rd of refraction to the eye. Ocular injuries, infections, and genetic factors affect corneal function and cause vision impairment. Presently, a variety of laser/non-laser surgeries, immunosuppressants, and/or corneal transplants are predominantly used to revive sight in human patients. The development of novel, precision-guided, and tissue-targeted non-surgical therapies promoting corneal repair and regeneration based on mechanistic understanding is of paramount importance to reduce the impact of global blindness. Research over the past decade revealed that modulation of pathological signaling pathways and factors by a variety of therapeutic delivery methods effectively treats corneal disorders including corneal scar/haze, inflammation, and angiogenesis in various pre-clinical animal models and are primed for human translation. This review discusses recent advances in the areas of corneal repair, restoration, and regeneration. Herein, we provide an overview of evolving approaches and therapeutic modalities that have shown great promise in reviving corneal transparency and function through the use of small drug molecules, gene therapy, nanomedicine, stem cells, trophic factors, exosomes, stromal equivalents, bioengineered stromal scaffolds, tissue adhesives, and 3D bioprinting.
引用
- Mohan RR, Kempuraj D, D'Souza S, et al. Corneal stromal repair and regeneration. Prog Retin Eye Res. 2022. PMID: 35649962. doi:10.1016/j.preteyeres.2022.101090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。